biotechnology

The Readout Elaine Chen

STAT Plus: Eli Lilly’s new maneuvers in GLP-1 treatment

Biotech Jason Mast

STAT Plus: Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics

Biotech Elaine Chen

STAT Plus: Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says

D.C. Diagnosis Sarah Owermohle

STAT Plus: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped

The Readout Elaine Chen

STAT Plus: Uniqure gets FDA OK to seek accelerated approval

Biotech Allison DeAngelis

STAT Plus: Oncology startup launches with $52 million, reflecting a new ‘austerity-driven’ financing reality

Health Angus Chen, Adam Feuerstein, Jonathan Wosen, and Meghana Keshavan

STAT Plus: Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

Exclusive Rachel Cohrs Zhang and John Wilkerson

STAT Plus: The pharma industry isn’t lobbying against RFK Jr.’s nomination for a top health role

The Readout Meghana Keshavan

STAT Plus: AbbVie drug succeeds in another Parkinson’s trial

Biotech Adam Feuerstein

STAT Plus: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments

Biotech Allison DeAngelis

STAT Plus: Young biotech venture firm raises $500 million for its second fund

Health Adam Feuerstein, Jonathan Wosen, Angus Chen, and Meghana Keshavan

STAT Plus: Biopharma leaders lay out vision for the future of blood cancer treatment

Politics John Wilkerson

STAT Plus: BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow

Pharmalot Ed Silverman

STAT Plus: European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Meghana Keshavan

STAT Plus: Lilly’s $3 billion investment in Wisconsin

The Readout Meghana Keshavan

STAT Plus: AstraZeneca replaces benched exec in China

Adam's Take Adam Feuerstein

STAT Plus: Why Applied Therapeutics has a credibility problem

Pharmalot Ed Silverman

STAT Plus: U.S. Patent Office pulls controversial rule to curb pharma patent abuse

The Readout Meghana Keshavan

STAT Plus: Compounding pharmacies rebut Novo’s FDA petition

Biotech Matthew Herper

STAT Plus: Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study

Biotech Jason Mast

STAT Plus: Arrakis CEO cites ‘cul-de-sacs’ on road to RNA-intercepting cancer drugs

The Readout Meghana Keshavan

STAT Plus: Sanofi pours $1 billion into China for insulin plant

The Readout Meghana Keshavan

STAT Plus: Despite probe, China reimbursing AstraZeneca drug

Biotech Allison DeAngelis

STAT Plus: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read today

Politics John Wilkerson

STAT Plus: It might be now or never for the BIOSECURE Act

Health Lizzy Lawrence

STAT Plus: Trump taps biotech investor Jim O’Neill for HHS deputy secretary

Health Rachel Cohrs Zhang

STAT Plus: Trump picks Stanford’s Jay Bhattacharya to lead NIH